InvestorsHub Logo
Followers 0
Posts 798
Boards Moderated 0
Alias Born 07/27/2018

Re: boston745 post# 26310

Tuesday, 08/20/2019 7:42:39 PM

Tuesday, August 20, 2019 7:42:39 PM

Post# of 41230
Found something that might be interesting here Boston.

Concurrent to the fall of zirconia, the need for high mechanical performance ceramic for femoral heads and other orthopedic components led to the development of ZTA composites. Starting from the early 2000's, being more or less confidential until 2005.



page 104

https://books.google.com/books?id=oa8YpRsD1kkC&printsec=frontcover&source=gbs_atb#v=onepage&q&f=false

This is in regards to development of Biolox delta. 2001 is the culmination of recalls that led to a full stop on zirconia detailed on page 103 due to shattering and sterilization issues. Looks like this is where Ceramtec takes market share away from companies like Morgan,Kyocera and Saint Gobain with a "superior ceramic".

What's interesting is the authors use of the word confidential in regards to development of a superior ceramic.

-----------------------------

What I`m looking at here is attempting to find a benchmark for timelines on development. Here it looks like 5 years. Due to the fact it's listed as "confidential development" That's tough to say 5 years is accurate. Also taking in to consideration there's probably incentive for rapid development for ceramtec to capitalize on zirconia failings and take market share away from the competition within this window of FDA and surgeons finding flaws with Zirconia.


yttria-stabilized ZTA composites versus hydrothermal aging may not be complete, to our knowledge no in vivo study has yet demonstrated any critical effect.



Well except for all the surgeons views "ceramics shatter" and the FDA's issues with Zimmers sterilization routines. But that's anecdotal evidence and borderline conspiratorial to say this is evidence for biolox delta's in vivo decomposition due to hydrothermal aging leading to shattering. "more research is needed"
but i would say that to maintain market share dominance. Both in regards to biolox delta and SINI's potential for in vivo degradation due to hydrothermal aging.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SINT News